RT Journal Article
SR Electronic
T1 Clinical presentation and evolution of COVID-19 in immunosuppressed patients. Preliminary evaluation in a North Italian cohort on calcineurin-inhibitors based therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.26.20080663
DO 10.1101/2020.04.26.20080663
A1 Cavagna, Lorenzo
A1 Bruno, Raffaele
A1 Zanframundo, Giovanni
A1 Gregorini, Marilena
A1 Seminari, Elena
A1 Di Matteo, Angela
A1 Rampino, Teresa
A1 Montecucco, Carlomaurizio
A1 Pelenghi, Stefano
A1 Cattadori, Barbara
A1 Pattonieri, Eleonora Francesca
A1 Vitulo, Patrizio
A1 Bertani, Alessandro
A1 Sambataro, Gianluca
A1 Vancheri, Carlo
A1 Bonetto, Valentina
A1 Monti, Maria Cristina
A1 Ticozzelli, Elena
A1 Turco, Annalisa
A1 Oggionni, Tiberio
A1 Corsico, Angelo
A1 Codullo, Veronica
A1 Morosini, Monica
A1 Gnecchi, Massimiliano
A1 Pellegrini, Carlo
A1 Meloni, Federica
YR 2020
UL http://medrxiv.org/content/early/2020/05/01/2020.04.26.20080663.abstract
AB The clinical course of COVID-19 in patients undergoing chronic immunosuppressive therapy is yet poorly known. We performed a monocentric cross-sectional study describing the clinical course of COVID-19 in a cohort of patients from northern Italy treated with calcineurin-inhibitors for organ transplantation or rheumatic diseases. Data were collected by phone call and clinical chart review between March 27th- 31st 2020. COVID-19 related symptoms, rynopharingeal swab, therapeutic changes and outcome were assessed in 384 consecutive patients (57% males; median age 61 years, IQR 48-69). 331 patients (86%) received solid organ transplantation (kidney n=140, 36%, heart n=100, 26%, lung n=91, 24%) and 53 (14%) had a rheumatic disease. Calcineurin inhibitors were the only immunosuppressant administered in 46 patients (12%). 14 patients developed a “confirmed COVID-19” (swab positivity) and 14 a “clinical COVID-19” (only typical symptoms). Fever (75%) and diarrhoea (50%) were the most common symptoms. Fourteen patients were hospitalized and 11 have already been dismissed. No patient required start/changes of the O2 therapy or developed superinfection. Only one patient, with metastatic lung cancer, died. In conclusion, COVID-19 showed a mild course in our cohort, with low mortality. Calcineurin inhibitor-based immunosuppressive regimens appear safe in this context and should not be discontinued.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request due to privacy/ethical restrictions